913 results on '"Thiede, C"'
Search Results
2. An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants
3. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
4. The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia
5. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD,NPM1- or biallelicCEBPA mutations
6. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB
7. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
8. Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML
9. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape
10. Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient
11. In patients over 50 years with intermediate or high-risk AML survival after allogeneic stem cell transplantation is not dependent on donor type (matched unrelated versus sibling donors)
12. P051 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB
13. GFI1 as a novel prognostic and therapeutic factor for AML/MDS
14. Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
15. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
16. P11.21.B Distinct age-related molecular and clinical features inIDH-Wildtype Glioblastoma
17. Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients
18. Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients
19. Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004
20. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations
21. Eradication of Helicobacter pylori and Stability of Remissions in Low-Grade Gastric B-Cell Lymphomas of the Mucosa-Associated Lymphoid Tissue: Results of an Ongoing Multicenter Trial
22. Evaluation of the long-term outcome of Helicobacter pylori -related gastric mucosa-associated lymphoid tissue (MALT) lymphoma
23. Use of p53 as Cancer Cell Target for Gene Therapy
24. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
25. Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
26. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial
27. P545: CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19
28. P470: NGS-BASED MINIMAL RESIDUAL DISEASE DETECTION IN PERIPHERAL BLOOD SHOWS GOOD PROGNOSTIC VALUE FOR OS AND EFS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECRUITED IN THE UNIFY TRIAL
29. S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
30. S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
31. P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS
32. P747: LR-MDS IS CHARACTERIZED BY DIFFERENTIAL EXPRESSION OF INFLAMMASOME-RELATED GENES IN SPECIFIC CELL POPULATIONS
33. Molecular Biology
34. Biologie und Klinik der MALT-Lymphome
35. Genomic characterisation of IDH-Wildtype Glioblastoma in different age groups
36. Clinical presentation, diagnosis and treatment of Helicobacter pylori-related gastric lymphoma
37. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
38. Analysis of Chimerism in the Early Posttransplantation Period in Cellular Subsets of Patients Undergoing Myeloablative and Non-Myeloablative (Metakine) Allogeneic Blood Stem Cell Transplantation (BSCT)
39. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
40. Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
41. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study
42. Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia
43. SETBP1 mutation analysis in 944 patients with MDS and AML
44. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups
45. Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy
46. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial
47. Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia
48. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways
49. Low frequency of calreticulin mutations in MDS patients
50. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.